All the Drug Class Drugs
Protein Kinase Inhibitor. Everolimus 2.5, 5, 10 mg. TABS: 30 x 2.5 mg, 5 mg, 10 mg. Tmt. to
be initiated by physician experienced
in the use of anticancer ther. Orally
once dly., at the same time ev. d. See
Tmt. pts. with advanced ren. cell
carcinoma aft. fail. of tmt. with sunitinib or
sorafenib. Tmt. pts. with SEGA assoc. with
tuberous sclerosis complex who req. ther.
but not candidates for curative surg.
resect. Effect. based on analys. of change
in SEGA vol. Clin. benefit in improvement
dis.-relat,. sympts/increase in overall
survival has not been demonstrat. Tmt.
progress. neuroendocrine tumors
pancreat. origin in pts. with unresect.,
locally advanced/metastat. dis. Safety/
effectivenss in tmt. carcinoid tumors have
not been established. Tmt. of horm.
receptor-pos., HER2/neu neg. advanc.
breast canc. in combi. with exemestane in
postmen. women w/o symp. visceral dis.
after recur. or progress. following nonsteroid.
aromat. inh.. Tmt. of adult pts.
with renal angiomyolipoma and tuberous
sclerosis comp., nor req. immediate surg.
Effectiv. of the drug in tmt. of renal
angiomyolipoma based on an analysis of
durable obj. respons. in pts. treat. for a
median of 8.3 mnths. Further follow-up of
pts. is req. to determine long-term
Tmt. of unresect., local. advanc. /metastat.,
well-different. (Grade 1/ Grade 2) nonfunct.
neuroendocrine tumour. of GI or
lung origin in adults with progress. dis.
C/I: Hypersens. to active substances,
other rapamycin derivs., excips.
Protein Kinase Inhibitor. Alectinib 150 mg. HARD CAPS.:240.
600 mg (4×150 mg caps.) ×2/d with food , max. dly. dose of 1200 mg). See lit.
Tmt. of pts. with ALK posit., local. advanc. or metast. non-small cell lung cancer (NSCLC) who progres. on or are intolerant to crizotinib. Alectinib as monother. - for the 1st -line tmt. of adult pts. with anaplastic lymphoma kinase (ALK)-posit. advanc. non-small cell lung cancer. (NSCLC).
Protein Kinase Inhibitor. Brigatinib 30 mg, 90 mg. F.C. TABS.: 30. The recom. dose regimen for is: 90 mg×1/d for the first 7 days;
If 90 mg is tolerat. during the first 7 d, incr. the dose to 180 mg ×1/d.
Admin. will cont. until dis. progres. or unaccept. toxicity.
If Brigatinib is interrupt. for 14 d. or longer for reasons other than ADR's, resume tmt. at 90 mg ×1/d for 7 d. before incr. to the prev. tolerated dose.
Tmt. of pts. with anaplastic lymphoma kinase (ALK)-positive metastat. non-small cell lung cancer (NSCLC) who have progres. on or are intolerant to crizotinib.
Protein Kinase Inhibitor. Bosutinib 100, 400, 500 mg. F.C. TABS.: 28 x 100 mg, 400 mg, 500 mg. Newly-diagn. CP Ph+ CML: The recommend. dose is 400×1/d.
CP, AP, or BP Ph+ CML with resistance or intoler.to prior ther.: The recomm. dose is 500 mg×1/d. Doses greater than 600 mg/day have not been studied and therefore should not be given. See lit.
Tmt. of adult pts. with: Newly-diagn. chron. phase (CP) Philadelphia chromos.-posit. chron. myelogenous leukaem. (Ph+ CML).
Chron. phase (CP), acceler. phase (AP), and blast phase (BP) Philadelphia chromos. posit. chron. myelogenous leukaem. (Ph+ CML) prev. treated with one/more tyrosine kinase inhib.(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropr. tmt. options.
C/I: Hypersens., Hepatic impair.
Protein Kinase Inhibitor. Cobimetinib Hemifumarate 20 mg. F.C. TABS.:63.
60 mg (3 tabs. of 20 mg) once dly., taken on a 28 day cycle. 21 consecutive d. (1st -21st day -tmt. period); follow.by a 7-day break (22nd -28th –tmt. break). Each subseq. tmt. cycle should start after the 7-day tmt. break has elapsed. See lit.
Indicat. for use in comb. with vemurafenib for the tmt. of adult pts. with unresectab. or metastat. melanoma with a BRAF V600 mutation.
Protein Kinase Inhibitor. Afatinib (as dimaleate) 20, 30, 40, 50 mg. F.C TABS: 7, 14, 28 × 20 mg, 30 mg, 40
mg, 50 mg.
40 mg 1 x dly., 3 hrs. before meal and at
least 1 h. after. May incr. up to 50 mg 1 x
dly after 3 wks. without serious adverse
events. Tmt. should be cont. until dis.
progres. or until no longer tolerat. By
the pt. see lit.
As monother. for the tmt. of: EGFR TKInaïve
adult pts. with local. advanc. or
metastat. NSCLC with activat. EGFR
mutation(s); Local. advance. or metast.
NSCLC of squamous histology progress. on
or after platin. -based chemother.
C/I: Hypersens., pregnancy, lact.